Recent Trials Guiding mRCC Treatment

Opinion
Video

Panelists discuss how recent clinical trials have shaped treatment algorithms for metastatic renal cell carcinoma (mRCC) by establishing the superiority of immunotherapy–tyrosine kinase inhibitor combinations over single-agent therapies across various risk groups.

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
2 experts are featured in this series.
Related Content